Additionally, tofacitinib, a broad-spectrum Janus kinase (JAK) inhibitor, has been suggested as a potential treatment for TGM1-associated autosomal recessive congenital ichthyosis (ARCI), characterized by elevated transepidermal water loss [78]. This evidence concerns the gene TGM1 and autosomal recessive congenital ichthyosis.